RecruitingPhase 1 / Phase 2NCT05919264
Rare condition
Craniopharyngioma
13
studies recruiting now
as of 7 Sept 2026
121
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
5 Jan 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT07316101
Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery
RecruitingPhase 2NCT05233397
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
RecruitingPhase 2NCT05465174
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
RecruitingPhase 2NCT05286788
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 13 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Craniopharyngioma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Craniopharyngioma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (BRAF, CTNNB1).
Treatments being studied
9 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Dabrafenib (Tafinlar)
Phase 2Methionine
Phase 2Trametinib (Mekinist)
Phase 2Vemurafenib (Zelboraf)
Phase 2Cobimetinib
Phase 2Peginterferon Alfa-2b (Peg-intron)
Phase 2Dextrose (Capd)
Phase 2Tovorafenib (Ojemda)
+ 1 more in development
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).